Chih-Tsueng He

Chih-Tsueng He

Auto-generated profile, based on publicly available information

Chih-Tsueng He

Department of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan, R.O.C.

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
YWYing Wu
Ying Wu
HGHe Gao
He Gao
HLHuaixing Li
Huaixing Li
YTYasuharu Tabara
Yasuharu Tabara
MNMasahiro Nakatochi
Masahiro Nakatochi
ETE Shyong Tai
E Shyong Tai
Blood levels of adiponectin, an adipocyte-secreted protein correlated with metabolic and cardiovascular risks, are highly heritable. Genome-wide association (GWA) studies for adiponectin levels have identified 14 loci harboring variants associated with blood levels of adiponectin. To identify novel adiponectin-associated loci, particularly those of importance in East Asians, we conducted a meta-analysis of GWA studies for adiponectin in 7827 individuals, followed by two stages of replications in 4298 and 5954 additional individuals. We identified a novel adiponectin-associated locus on chromosome 10 near WDR11-FGFR2 (P = 3.0 × 10−14) and provided suggestive evidence for a locus on chromosome 12 near OR8S1-LALBA (P = 1.2 × 10−7). Of the adiponectin-associated loci previously described, we confirmed the association at CDH13 (P = 6.8 × 10−165), ADIPOQ (P = 1.8 × 10−22), PEPD (P = 3.6 × 10−12), CMIP (P = 2.1 × 10−10), ZNF664 (P = 2.3 × 10−7) and GPR109A (P = 7.4 × 10−6). Conditional analysis at ADIPOQ revealed a second signal with suggestive evidence of association only after conditioning on the lead SNP (Pinitial = 0.020; Pconditional = 7.0 × 10−7). We further confirmed the independence of two pairs of closely located loci (<2 Mb) on chromosome 16 at CMIP and CDH13, and on chromosome 12 at GPR109A and ZNF664. In addition, the newly identified signal near WDR11-FGFR2 exhibited evidence of association with triglycerides (P = 3.3 × 10−4), high density lipoprotein cholesterol (HDL-C, P = 4.9 × 10−4) and body mass index (BMI)-adjusted waist–hip ratio (P = 9.8 × 10−3). These findings improve our knowledge of the genetic basis of adiponectin variation, demonstrate the shared allelic architecture for adiponectin with lipids and central obesity and motivate further studies of underlying mechanisms.

18 May 2004 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
CHChih‐Tsueng He
Chih‐Tsueng He
AHAn‐Tsz Hsieh
An‐Tsz Hsieh
DPDee Pei
Dee Pei
YHYi‐Jen Hung
Yi‐Jen Hung
LWLing‐Yi Wu
Ling‐Yi Wu
SKShi-Wen Kuo
Shi-Wen Kuo

1 January 2014 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
CHChih-Tsueng He
Chih-Tsueng He
CLChien-Hsing Lee
Chien-Hsing Lee
CHChang-Hsun Hsieh
Chang-Hsun Hsieh
FHFone-Ching Hsiao
Fone-Ching Hsiao
PKPhilip Kuo
Philip Kuo
YHYi-Jen Hung
Yi-Jen Hung
The aim of this cross-sectional study was to investigate the relationship between soluble form of receptor for advanced glycation end products (sRAGE), obesity, and metabolic syndrome (MetS) in adolescents. A total of 522 male and 561 female adolescents were enrolled into the final analyses. Anthropometric parameters, blood pressure, blood biochemistry, fasting insulin, and plasma sRAGE levels were measured. In males, sRAGE was significantly and inversely correlated with waist circumference (WC), body mass index (BMI), systolic blood pressure, triglyceride (TG), low density lipoprotein cholesterol (LDL-C), and homeostasis model assessment-insulin resistance (HOMA-IR). Only WC and BMI were significantly and inversely correlated with sRAGE in females. Using linear regression analysis adjusting for age and gender, significant association was found between sRAGE and WC, BMI, TG, LDL-C, and HOMA-IR in adolescents of either gender (P<0.05). This association was abolished when further adjusting BMI. In addition, sRAGE was significantly and inversely correlated with the increasing number of components of MetS in males (Pfor trend = 0.006) but not in females (Pfor trend = 0.422). In conclusion, plasma sRAGE is associated with obesity and MetS among adolescents. BMI may be the most important determinant of sRAGE levels in adolescents.

1 January 2005 in Endocrine Research
Verified
Journal Article
Closed access
CLChien-Hsing Lee
Chien-Hsing Lee
SKShi-Wen Kuo
Shi-Wen Kuo
YHYi-Jen Hung
Yi-Jen Hung
CHChang-Hsun Hsieh
Chang-Hsun Hsieh
CHChih-Tsueng He
Chih-Tsueng He
DPDee Pei
Dee Pei
Our understanding of the effect of androgens on insulin action and glucose metabolism is incomplete. Several different models and methods have been used to study androgen effects, with some studies indicating that higher testosterone levels are associated with increased insulin resistance. In polycystic ovary syndrome, where high testosterone levels are frequently found, affected patients have a higher risk of diabetes. In contrast, increased insulin resistance was found in both hypergonadotropic and hypogonadotropic men with hypoandrogenism, patients with Klinefelter's syndrome and men with idiopathic gonadotropin deficiency. Insulin resistance is considered to be one of the cornerstones in the state that ultimately leads to clinically established type 2 diabetes mellitus. In addition, men with type 2 diabetes have relative hypogonadism. Therefore, supplementation with testosterone might play a role in improving both insulin resistance and hypogonadism. The study population consisted of 11 male patients with type 2 diabetes. Their mean age was 57.7 ± 3.41 years, the body mass index (BMI) was 24.4 ± 1.02 kg/m2, and the waist-to-hip ratio (W/H) was 0.91 ± 0.05. The patients were all treated with oral hypoglycemic agents. The men received androgen injections every 3 weeks intramuscularly for 12 weeks. The injections were testosterone depot 100 mg/3 weeks. Insulin sensitivity, glucose effectiveness and area under acute insulin response were calculated from "minimal model" algorithms. There were no significant differences in the value of BMI, W/H ratios, plasma lipid concentrations, testosterone, homeostasis model assessment (HOMA) of insulin sensitivity, and beta-cell function, before and after supplementation of testosterone. Furthermore, the insulin sensitivity (SI) (1.04 ± 0.25, 1.11 ± 0.36 x 10−5 min−1/pM; p = 0.43), glucose effectiveness (EG) (0.018 ± 0.003, 0.017 ± 0.002 min−1; p = 0.29), and acute insulin response (AIR) after a glucose load (45.7 ± 24.3, 50.1 ± 32.5 pM; p = 0.45) did not change significantly after supplementation with testosterone. In our study, there was no improvement of SI, EG, and AIR after 3 months of Testosterone Depot treatment in type 2 diabetes, but we believe that duration and dosage of the androgen therapy might play an important role in improving insulin sensitivity. The mechanisms by which testosterone causes insulin resistance is unknown, and larger studies on androgen treatment in type 2 diabetic patients are necessary.

11 September 2012 in Clinical Pediatrics
Verified
Journal Article
Closed access
CLChin-Jung Lin
Chin-Jung Lin
NCNain Feng Chu
Nain Feng Chu
YHYi-Jen Hung
Yi-Jen Hung
JCJin-Biou Chang
Jin-Biou Chang
CHChih-Tsueng He
Chih-Tsueng He
CHChang-Hsun Hsieh
Chang-Hsun Hsieh
Objectives. Retinol-binding protein 4 (RBP4) has a role in the development of insulin resistance (IR), type 2 diabetes, obesity, and metabolic syndrome among adults. However, data among adolescents are limited, and the effects of gender and sex hormones on RBP4 are not well defined. Materials/Methods. A total of 1082 adolescents were enrolled and categorized based on their body mass index. Blood samples were collected, and biochemical characteristics, sex hormones, RBP4 concentrations, and IR were determined. Results. Testosterone and estradiol were not directly correlated with RBP4 concentrations in both genders. Multivariate regression analysis revealed that fasting plasma glucose (FPG), triglyceride (TG), and testosterone levels were independently associated with RBP4 concentrations in boys; also, there was a trend of increasing RBP4 levels with the severity of obesity. Conclusion. Plasma RBP4 concentrations correlated with obesity and cardiovascular risk factors, predominantly evident in boys. Testosterone, FPG, and TG levels were independent predictors of RBP4 concentrations.

1 August 2003 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
SKShi-Wen Kuo
Shi-Wen Kuo
YHYi-Jen Hung
Yi-Jen Hung
AHAn-Tsz Hsieh
An-Tsz Hsieh
LWLing-Yi Wu
Ling-Yi Wu
CHChang-Hsun Hsieh
Chang-Hsun Hsieh
WLWei-Cheng Lian
Wei-Cheng Lian
To evaluate the effect of the sustained-release formulation of indapamide (indapamide SR) in type 2 diabetic patients with mild-to-moderate hypertension and its possible side effects, particularly on glucose metabolism and lipid profiles. A total of 64 patients randomly received 1.5 mg of indapamide SR or placebo once daily for 3 months. The effects were evaluated by 24-h ambulatory blood pressure monitor, fasting blood sampling for biochemistry, lipid profiles, and frequently sampled intravenous glucose tolerance test. The changes in standing and supine blood pressure (BP) were significant (154.7 ± 9.4/94 ± 2.9 mm Hg v 134.4 ± 5.1/82.4 ± 5 mm Hg and 155 ± 9.8/94.6 ± 3.6 mm Hg v 135.1 ± 4.9/82.1 ± 4.7 mm Hg) in the indapamide group, but not in the placebo group. According to the 24-h ambulatory blood pressure monitor reading, a significant reduction was observed in not only in the whole-day mean BP (mean systolic BP/mean diastolic BP, 149 ± 19.3/87.6 ± 11.3 mm Hg v 135.7 ± 12.6/79.6 ± 9 mm Hg) but also the whole-day mean median arterial pressure (109 ± 12.7 mm Hg v 98.7 ± 8.2 mm Hg) for the indapamide group, but not the placebo group. There were no changes in biochemical data including serum sodium, potassium, chloride, uric acid, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine, lipid profiles, fasting blood glucose, insulin, hemoglobin Alc, and glucose metabolism parameters (insulin sensitivity, glucose effectiveness, and acute insulin response) from frequently sampled intravenous glucose tolerance test after indapamide or placebo therapy. Indapamide SR can significantly lower the whole-day BP in hypertensive patients with type 2 diabetes. Also, it did not alter or aggravate patients’ lipid profiles, glucose metabolism, and did not exert possible side effects of hypokalemia and hyperuricemia. Therefore, monotherapy with indapamide SR should be suggested in type 2 diabetic patients with mild-to-moderate hypertension.